Skip to main navigation Skip to search Skip to main content

Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women

  • Valentina A. Zavala
  • , Sandro Casavilca-Zambrano
  • , Jeannie Navarro-Vásquez
  • , Carlos A. Castañeda
  • , Guillermo Valencia
  • , Zaida Morante
  • , Monica Calderón
  • , Julio E. Abugattas
  • , Henry Gómez
  • , Hugo A. Fuentes
  • , Ruddy Liendo-Picoaga
  • , Jose M. Cotrina
  • , Claudia Monge
  • , Silvia P. Neciosup
  • , Scott Huntsman
  • , Donglei Hu
  • , Sixto E. Sánchez
  • , Michelle A. Williams
  • , Angel Núñez-Marrero
  • , Lenin Godoy
  • Aaron Hechmer, Adam B. Olshen, Julie Dutil, Elad Ziv, Jovanny Zabaleta, Bizu Gelaye, Jule Vásquez, Marco Gálvez-Nino, Daniel Enriquez-Vera, Tatiana Vidaurre, Laura Fejerman

    Research output: Contribution to journalArticlepeer-review

    5 Scopus citations

    Abstract

    Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/ Black or Non-Hispanic White women. An Indigenous American breast cancer-protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47-0.59], as well as the lower odds of developing hormone receptor negative (HR-) versus HR+ disease (OR, 0.77; 95% CI, 0.61-0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51-0.92), HR-HER2+ (OR, 0.63; 95% CI, 0.44-0.90) and HR-HER2- (OR, 0.77; 95% CI, 0.56-1.05) compared with HR+HER2-. Inclusion of other risk-associated variants did not change these observations. Conclusions: The rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR- and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. Impact: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.

    Original languageEnglish
    Pages (from-to)1602-1609
    Number of pages8
    JournalCancer Epidemiology Biomarkers and Prevention
    Volume31
    Issue number8 August
    DOIs
    StatePublished - 1 Aug 2022

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women'. Together they form a unique fingerprint.

    Cite this